OncoDaily

🎗️ What Really Changes in Breast Oncology After ESMO 2026? @myESMO - European Society for Medical Oncology Congress 2026 has delivered major updates across early and metastatic breast cancer, from the six-year NATALEE survival analysis to a rapidly expanding generation of antibody-drug conjugates. 📊 Key findings shaping the field: 🔹 NATALEE: Six-year OS of 91.9% vs 89.7%, strengthening long-term evidence for adjuvant ribociclib. 🔹 HORIZON-Breast06: Median PFS of 16.4 vs 6.8 months with trastuzumab rezetecan in HER2-low advanced disease. 🔹 PANKU-Breast01: A 59% reduction in the hazard of progression or death with the bispecific ADC izalontamab brengitecan. 🔹 OptiTROP-Breast01: Sustained OS benefit with sacituzumab tirumotecan in previously treated metastatic TNBC. 🔹 KEYNOTE-B49 and postMONARCH: Important reminders that improvements in disease control do not necessarily establish an overall survival advantage. But the next challenge is larger than identifying another effective treatment. How do we select the right patient, choose the right ADC, sequence therapies after resistance, and balance benefit against toxicity? In our new OncoDaily Breast editorial, we examine which findings strengthen current practice, which remain investigational, and what oncologists should take away from Madrid. oncodaily.com/breast-oncolog… #ESMO2026 #BreastCancer #OncoDailyBreast #PrecisionOncology #NATALEE #HER2Low #TNBC #ADCs #ClinicalOncology #BreastOncology